Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M37,078Revenue (TTM) $M20,292Net Margin (%)8.9Altman Z-Score0.8
Enterprise Value $M77,895EPS (TTM) $1.7Operating Margin %15.9Piotroski F-Score3
P/E(ttm)21.1Beneish M-Score-2.0Pre-tax Margin (%)12.8Higher ROA y-yN
Price/Book1.210-y EBITDA Growth Rate %11.2Quick Ratio0.6Cash flow > EarningsY
Price/Sales1.75-y EBITDA Growth Rate %2.5Current Ratio0.9Lower Leverage y-yN
Price/Free Cash Flow7.3y-y EBITDA Growth Rate %162ROA % (ttm)2.9Higher Current Ratio y-yN
Dividend Yield %3.7PEG8.4ROE % (ttm)5.4Less Shares Outstanding y-yN
Payout Ratio %79.0Shares Outstanding M1,015ROIC % (ttm)5.6Gross Margin Increase y-yN

Gurus Latest Trades with TEVA

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
TEVANWQ Managers 2016-09-30 Add0.66%$46.01 - $55.45
($52.17)
$ 36.53-30%Add 58.75%2,663,631
TEVAJohn Paulson 2016-09-30 Reduce-0.36%$46.01 - $55.45
($52.17)
$ 36.53-30%Reduce -4.15%16,076,900
TEVABarrow, Hanley, Mewhinney & Strauss 2016-09-30 Add0.27%$46.01 - $55.45
($52.17)
$ 36.53-30%Add 17.05%26,570,988
TEVAMichael Price 2016-09-30 Add0.18%$46.01 - $55.45
($52.17)
$ 36.53-30%Add 6.59%469,300
TEVAVanguard Health Care Fund 2016-09-30 Add0.04%$46.01 - $55.45
($52.17)
$ 36.53-30%Add 6.13%6,746,400
TEVADavid Dreman 2016-09-30 Reduce-0.04%$46.01 - $55.45
($52.17)
$ 36.53-30%Reduce -3.92%31,969
TEVARonald Muhlenkamp 2016-09-30 Reduce-0.02%$46.01 - $55.45
($52.17)
$ 36.53-30%Reduce -0.50%175,770
TEVAKeeley Asset Management Corp 2016-09-30 Reduce$46.01 - $55.45
($52.17)
$ 36.53-30%Reduce -2.23%56,869
TEVAJulian Robertson 2016-06-30 Sold Out -4.78%$48.53 - $57.25
($53.24)
$ 36.53-31%Sold Out0
TEVAJohn Paulson 2016-06-30 Reduce-1.55%$48.53 - $57.25
($53.24)
$ 36.53-31%Reduce -18.58%16,773,800
TEVABarrow, Hanley, Mewhinney & Strauss 2016-06-30 Add1.03%$48.53 - $57.25
($53.24)
$ 36.53-31%Add 143.69%22,700,812
TEVAFirst Eagle Investment 2016-06-30 Reduce-0.26%$48.53 - $57.25
($53.24)
$ 36.53-31%Reduce -99.99%200
TEVANWQ Managers 2016-06-30 Reduce-0.24%$48.53 - $57.25
($53.24)
$ 36.53-31%Reduce -14.45%1,677,841
TEVAKeeley Asset Management Corp 2016-06-30 Add0.03%$48.53 - $57.25
($53.24)
$ 36.53-31%Add 32.85%58,169
TEVARonald Muhlenkamp 2016-06-30 Reduce-0.01%$48.53 - $57.25
($53.24)
$ 36.53-31%Reduce -0.29%176,655
TEVADavid Dreman 2016-06-30 Reduce$48.53 - $57.25
($53.24)
$ 36.53-31%Reduce -2.09%33,274
TEVAJulian Robertson 2016-03-31 Reduce-2.02%$53.5 - $65.86
($58.8)
$ 36.53-38%Reduce -40.16%356,200
TEVANWQ Managers 2016-03-31 Add0.49%$53.5 - $65.86
($58.8)
$ 36.53-38%Add 42.10%1,961,208
TEVAFirst Eagle Investment 2016-03-31 Reduce-0.4%$53.5 - $65.86
($58.8)
$ 36.53-38%Reduce -56.18%1,915,660
TEVADavid Dreman 2016-03-31 Buy 0.21%$53.5 - $65.86
($58.8)
$ 36.53-38%New holding33,983
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

TEVA is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


TEVA: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Quarterly/Annual Reports about TEVA:

    News about TEVA:

    Articles On GuruFocus.com
    Teva Is a Hold Nov 30 2016 
    Buy Health Care Now? It All Depends on the Election Nov 07 2016 
    John Paulson’s Health Care Picks Plunge in Flat Year for Sector Oct 06 2016 
    Allergan: An Undervalued Powerhouse Aug 28 2016 
    A Comprehensive Look at Dividend Growth Stock Valuations Sector by Sector: Part 2 Aug 26 2016 
    Swiss Generics Manufacturer Has Strong 1st Half of Year Aug 22 2016 
    Allergan Narrowly Beats Earnings, Thanks to Sales Surge Aug 09 2016 
    Siegfried Holdings, Held by Tweedy Browne, Way Undervalued Jul 22 2016 
    Andreas Halvorsen Buys Facebook, Amazon, MasterCard Jun 14 2016 
    Growing Generic Drug Market a Good Opportuity for 2 India Firms May 30 2016 

    More From Other Websites
    Analysts Are Bullish on Valeant Dec 02 2016
    Should You Avoid Suncor Energy Inc. (USA) (SU)? Dec 01 2016
    Corruption Currrents: Tracking Trump's Conflicts of Interest Dec 01 2016
    SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against... Dec 01 2016
    Teva Is a Hold Nov 30 2016
    Israeli Cannabis Inhaler May Get Tested With Opium Poppy Next Nov 30 2016
    Teva to Present Oncology Data at the 2016 American Society of Hematology (ASH) Annual Meeting &... Nov 30 2016
    Teva drugs help boost Mayne revenue Nov 28 2016
    Teva drugs help Mayne to strong start Nov 28 2016
    Teva to Market Medical Marijuana Inhaler in Israel Nov 28 2016
    SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against... Nov 28 2016
    How to buy the biggest losers Nov 28 2016
    Short Sellers Hike Their Bets in Most Major Pharma Stocks Nov 28 2016
    Teva Pharm to market medical cannabis inhaler in Israel Nov 28 2016
    SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From... Nov 27 2016
    SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Teva... Nov 25 2016
    Is Petroleo Brasileiro SA Petrobras (ADR) (PBR) A Good Stock to Buy? Top Investors Think So Nov 25 2016
    Do Hedge Funds Love Teva Pharmaceutical Industries Ltd (ADR) (TEVA)? Nov 25 2016
    Patent Litigations to Delay Teva’s New Product Launches Nov 24 2016
    Teva’s Research Pipeline to Culminate in Many New Drug Launches? Nov 24 2016
    Teva Leads the Industry in First-to-File Applications in 2016 Nov 24 2016
    Biosimilar Business May Be a Strong Growth Opportunity for Teva Nov 23 2016
    Teva trims 2016 outlook on drug launch delays Nov 15 2016
    Teva misses Street 3Q forecasts Nov 15 2016
    Israeli billionaire Nacht bets big money on another Teva in healthcare Nov 15 2016
    ISS Mexico wins contract with Teva Pharmaceuticals Nov 10 2016
    Regeneron and Teva Provide Update on Fasinumab Clinical Development Programs Oct 17 2016
    Teva Receives Positive Opinion from European Medicines Agency’s Committee for Medicinal Products... Oct 17 2016
    Teva and Celltrion Announce Exclusive Biosimilar Commercial Partnership Oct 06 2016
    Deals of the day- Mergers and acquisitions Oct 05 2016
    Teva to sell Allergan's generics business in UK, Ireland for $769 million Oct 05 2016
    Teva to sell Allergan's generics business in UK, Ireland for $769 million Oct 05 2016
    Teva to sell Allergan's generics business in UK, Ireland for $769 million Oct 05 2016
    Teva Announces Sale of UK and Ireland Actavis Assets and Operations Oct 05 2016
    Regeneron and Teva Announce Global Collaboration to Develop and Commercialize Fasinumab, an... Sep 20 2016
    Teva, Intel to develop wearable tech for Huntington's disease Sep 15 2016
    Teva, Intel to develop wearable technology for Huntington's disease Sep 15 2016
    Teva and UGG Unveil Hybrid Collection Sep 15 2016
    Teva to Present Latest Data in Multiple Sclerosis at 2016 ECTRIMS Congress in London Sep 07 2016
    MDxHealth and Teva Pharmaceuticals Sign Distribution Agreement for SelectMDx in Israel Aug 31 2016
    Teva to Present New Respiratory Data at the 2016 European Respiratory Society (ERS) International... Aug 30 2016
    Teva Pharm eyes more acquisitions after buying Allergan's generics business Aug 04 2016
    Dr. Reddy’s Completes Acquisition of Product Portfolio from TEVA Aug 03 2016
    Allergan to sell Anda drug distribution business to Teva Aug 03 2016
    Teva completes $40 bn purchase of Allergan generics arm Aug 02 2016
    Teva completes $40 bn purchase of Allergan generics arm Aug 02 2016
    Teva, Allergan win U.S. antitrust approval for generics deal Jul 27 2016
    Teva, Allergan win U.S. antitrust approval for generics deal Jul 27 2016
    Teva, Allergan win U.S. antitrust approval for generics deal Jul 27 2016
    Teva expect to close $40.5B Allergan generic deal next week Jul 27 2016
    Five high-grade issuers announce deals Jul 20 2016
    TEVA and Antares Pharma Announce Launch of Generic Imitrex in the United States Jun 27 2016
    Sagent Pharmaceuticals Acquires Product Portfolio From Teva Pharmaceutical Industries Ltd. Jun 16 2016
    Mesoblast shares tank after Teva exit Jun 14 2016
    Mesoblast shares drop on outlook concerns Jun 13 2016
    Teva stops selling migraine patch after reports of burns Jun 13 2016
    Dr. Reddy’s to acquire product portfolio from TEVA for US Market Jun 11 2016
    Dr Reddy's in $350 mln deal to buy 8 U.S. drugs from Teva, Allergan Jun 11 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)